<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315780</url>
  </required_header>
  <id_info>
    <org_study_id>16730</org_study_id>
    <secondary_id>H9X-JE-GBGK</secondary_id>
    <nct_id>NCT03315780</nct_id>
  </id_info>
  <brief_title>A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes</brief_title>
  <official_title>A Phase 4 Study to Evaluate Glucodynamic Effects of Dulaglutide in Japanese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese
      participants with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Glucose Area Under the Concentration Versus Time Curve from Time Zero to 4 Hours (AUC[0-4h])</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in glucose AUC(0-4h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Blood Glucose</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Postprandial Blood Glucose</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in postprandial blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Insulin</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-Peptide</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in c-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glucagon</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triglyceride</measure>
    <time_frame>Baseline, 4 Weeks</time_frame>
    <description>Change from baseline in triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Develop Hypoglycemic Events</measure>
    <time_frame>Baseline through 4 weeks</time_frame>
    <description>Number of participants who develop hypoglycemic events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dulaglutide, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dulaglutide and placebo administered subcutaneously (SQ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo and dulaglutide administered SQ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Dulaglutide, Placebo</arm_group_label>
    <arm_group_label>Placebo, Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SQ</description>
    <arm_group_label>Dulaglutide, Placebo</arm_group_label>
    <arm_group_label>Placebo, Dulaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes (based on the World Health Organization [WHO] diagnostic
             criteria) for at least 1 year.

          -  Have diet and exercise therapy only (no oral antihyperglycemic medication for at least
             3 months prior to screening).

          -  Have a fasting blood glucose value of ≥120 and ≤200 milligrams per deciliter (mg/dL)
             at screening.

          -  Have a screening body weight of ≥50 and ≤80 kilograms.

        Exclusion Criteria:

          -  Have known allergies to dulaglutide, or other glucagon-like peptide-1 (GLP-1) receptor
             agonists.

          -  Have had a clinically significant cardiovascular disease.

          -  Have a known clinically significant gastric emptying abnormality or have undergone
             gastric bypass surgery or restrictive bariatric surgery.

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease.

          -  Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were
             diagnosed with any type of acute pancreatitis.

          -  Have an estimated glomerular filtration rate (eGFR) &lt;30 milliliters/minute/1.73 meter
             squared.

          -  In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

